Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
By Mandi Murph Treatment may be changing for patients with Stage III melanoma. Recent clinical trial results show improved outcomes…
Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN